SkinStylus is already FDA-cleared to improve the appearance of surgical or traumatic hypertrophic scars on the abdomen in adults aged 22 years and older. 

The U.S. Food and Drug Administration (FDA) has cleared The Beauty Health Company’s SkinStylus microneedling device for use on facial acne scarring in Fitzpatrick skin types I, II, and III in patients aged 22 years and older.

SkinStylus is already FDA-cleared to improve the appearance of surgical or traumatic hypertrophic scars on the abdomen in adults aged 22 years and older. 

“SkinStylus’ new facial indication for acne scarring is a testament to BeautyHealth’s innovation track record, proven brand building expertise, and our commitment to creating the future of skin health,” says BeautyHealth President and Chief Executive Officer Andrew Stanleick, in a news release. “Our goal is to become the world’s leading beauty, health and wellness platform by bringing together incredible brands and growing them into category leaders. This SkinStylus indication further unlocks the potential of the highly complementary treatments in our multi-brand ecosystem and positions SkinStylus for exponential growth in the years ahead.”